ArticleCureus2024
Aggressive Mesenchymal Chondrosarcoma of the Rib With Early Skeletal Metastases: A Diagnostic Challenge.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal chondrosarcoma (MCS) is a rare, aggressive subtype of chondrosarcoma characterized by biphasic histology, often misdiagnosed due to its rarity and histological resemblance to other small round cell tumors. It predominantly affects adolescents and young adults. We report a 27-year-old male presenting with a progressively enlarging, painless mass in the right inframammary region, initially attributed to muscular strain. Over one month, the mass rapidly increased in size, accompanied by mild pain exacerbated by movement. Physical examination revealed a firm, non-tender mass approximately 10 x 5 cm in diameter between the sixth and seventh ribs. Contrast-enhanced CT revealed a large expansile lytic lesion of the right sixth rib (10 × 5.5 cm) with cortical destruction, pathological fracture and soft tissue invasion into surrounding musculature. Core needle biopsy revealed a biphasic tumor comprising undifferentiated mesenchymal cells and islands of well-differentiated hyaline cartilage. Immunohistochemical staining showed positivity for vimentin, CD99 and S100 protein with a high Ki-67 proliferation index (30-40%). These findings were consistent with MSC. 18-Fluorodeoxyglucose-positron emission tomography (FDG-PET) scan detected widespread skeletal metastases involving the spine, humerus, scapula, ribs, pelvis and femur. A multidisciplinary team initiated neoadjuvant anthracycline-based chemotherapy to reduce tumor burden and manage systemic disease, with plans for potential surgical intervention upon reassessment. Given the typically poor prognosis associated with MCS, it should be considered in the differential diagnosis of bone tumors in young adults presenting with atypical musculoskeletal masses. Prompt diagnostic workup, including advanced imaging and comprehensive histopathological and immunohistochemical analysis, is essential for accurate diagnosis. A multidisciplinary approach to management is imperative to address the aggressive nature of MCS. Early detection and intervention remain key factors in enhancing survival rates and quality of life for patients afflicted with this formidable malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.